このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

心臓サルコイドーシス多施設前向きコホート (CHASM-CS)

2026年10月30日 更新者:Ottawa Heart Institute Research Corporation

心臓サルコイドーシス多施設前向きコホート研究

Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.

There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.

A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.

調査の概要

状態

募集

条件

詳細な説明

Baseline assessment of Clinically Manifest CS patients consists of: history, echocardiogram, ECG, chest CT scan, FDG-PET scan, blood for biomarkers within 2 months of the PET scan, cardiac MRI and possibly a signal average ECG and biopsy (encouraged-either endomyocardial or extra-cardiac).

Follow-up and clinical management of clinically manifest patients diagnosed with CS will occur at 3-6 months with a repeat FDG-PET scan and blood biomarkers. Follow-up will then be annually with an echo and ECG. Treatment with steroids/immunosuppressants and device therapy will be at the discretion of the treating physician.

Baseline assessment of patients diagnosed with extra-cardiac sarcoidosis and being screened for CS consists of: history, echocardiogram, ECG, holter, chest CT scan, biopsy, and cardiac MRI (CMR). If the CMR is suggestive of CS the patient will be have a FDG-PET scan done and be followed as a Clinically Silent patient. They will be contacted every 2 years. If the CMR is negative the patient will be followed as a extra-cardiac sarcoidosis patient with no evidence of CS and be in the control group. They will be contacted at 5 years and at the time of study completion.

All patients will be followed until the last patient recruited has been followed for 4 years.

The occurrence of the primary and secondary outcomes will be assessed in treated and untreated patients.

There will be 2 imaging core labs. The PET core lab will be located at UOHI under the direction of Dr. Robert Beanlands. The CMR core lab will be under the direction of Dr. Mathias Friedrich (McGill University). All scans will be read in the core labs by physicians who are blinded to the clinical details of the patients.

The Biomarker core lab will be at The University of Ottawa Heart Institute under the leadership of Dr P Liu.

研究の種類

観察的

入学 (推定)

1500

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Janine E Ryan, BA(H), CCRP
  • 電話番号:17077 613-696-7000
  • メール:jryan@ottawaheart.ca

研究連絡先のバックアップ

研究場所

    • Alberta
      • Calgary、Alberta、カナダ、T2N 2T9
        • 募集
        • Libin Cardiovascular Institute of Alberta
        • 主任研究者:
          • Russell Quinn, MD
        • コンタクト:
          • Russell Quinn, MD
      • Edmonton、Alberta、カナダ、T6G 2B7
        • 募集
        • University of Alberta Hospital
        • コンタクト:
          • Tomascz Hruczkowski, MD
        • 主任研究者:
          • Tomascz Hruczkowski, MD
    • British Columbia
      • Vancouver、British Columbia、カナダ、V5Z 1M9
        • 募集
        • St. Paul's Hospital
        • コンタクト:
          • Shanta Chakrabarti, MD
        • 主任研究者:
          • Shanta Chakrabarti, MD
    • Nova Scotia
      • Halifax、Nova Scotia、カナダ、B3H 3A7
        • 募集
        • QEII Health Sciences Center
        • 主任研究者:
          • Ciorsti MacIntyre, MD
        • コンタクト:
          • Kim Anderson, MD
    • Ontario
      • Hamilton、Ontario、カナダ、L8L 2X2
        • 募集
        • Hamilton Health Sciences Centre
        • 主任研究者:
          • Jeff Healey, MD
        • コンタクト:
          • Gerard Cox, MD
        • コンタクト:
          • Jeff Healey, MD
      • London、Ontario、カナダ、N6A 5A5
        • 募集
        • London Health Sciences Centre
        • コンタクト:
          • Lorne Gula, MD
        • 主任研究者:
          • Lorne Gula, MD
      • Newmarket、Ontario、カナダ、L3Y 2P9
        • 募集
        • Southlake Regional Health Centre
        • コンタクト:
          • Bernice Tsang, MD
        • 主任研究者:
          • Bernice Tsang, MD
      • Ottawa、Ontario、カナダ、K1Y 4W7
        • 募集
        • University of Ottawa Heart Institute
        • コンタクト:
        • 主任研究者:
          • David Birnie, MD
        • コンタクト:
      • Toronto、Ontario、カナダ、M5G 2C4
        • 募集
        • Toronto General Hospital
        • コンタクト:
          • Andrew Ha, MD
        • 主任研究者:
          • Andrew Ha, MD
    • Quebec
      • Montreal、Quebec、カナダ、H1T 1C8
        • 募集
        • Montreal Heart Institute
        • コンタクト:
          • Lena Rivard, MD
        • 主任研究者:
          • Lena Rivard, MD
      • Montreal、Quebec、カナダ、H3G 1A4
        • 募集
        • McGill University Health Centre
        • コンタクト:
          • Fiorella Rafti
        • 主任研究者:
          • Martin L Bernier, MD
      • Montreal、Quebec、カナダ、H2W 1T8
        • まだ募集していません
        • Centre Hospitalier de l"Universite de Montreal-Hotel Dieu
        • コンタクト:
          • Julie Fleury, RN
        • 主任研究者:
          • Benoit Coutu, MD
    • Saskatchewan
      • Regina、Saskatchewan、カナダ、S4P 0W5
        • 募集
        • Prairie Vascular Research Inc-Regina General Hospital
        • コンタクト:
        • 主任研究者:
          • Andrea Lavoie, MD
      • Sapporo、日本、060-8638
        • 募集
        • Hokkaido University
        • コンタクト:
        • 主任研究者:
          • Ichizo Tsujino, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~99年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

確率サンプル

調査対象母集団

Electrophysiology Service patients

説明

Inclusion Criteria:

To diagnose Clinically Manifest CS all following criteria must be met:

(i) Positive biopsy* for Sarcoid (either EMB or extra-cardiac) AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical features:

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%) AND (iv) No alternative explanation for clinical features AND (v) FDG-PET suggestive of active CS

To diagnose clinically silent CS all of the following criteria must be met

(i) Biopsy proven extra-cardiac sarcoidosis

AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis

AND (iii) CMR suggestive of cardiac sarcoidosis

AND (iv) Does not have criteria for clinically manifest CS ie. should not have any of following

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%)

Patients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no evidence of CS' and followed as control

Exclusion Criteria:

  • unable or unwilling to provide informed consent
  • patients who are pregnant or lactating
  • patients with known claustrophobia
  • age < 18 years

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
CS screened as underlying etiology
  1. Patients with active Clinically Manifest CS
  2. Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Primary Outcome for ALL Patients
時間枠:Through study completion, on average 10 years

The primary outcome is a composite of cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation.

Heart failure hospitalization is defined as admission to hospital > 24 hours and received treatment for heart failure.

Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Secondary Outcomes for ALL Patients
時間枠:Through study completion, on average 10 years

1. Total mortality Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for ALL Patients
時間枠:Through study completion, on average 10 years

2. Individual components of primary outcome (cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
時間枠:Through study completion, on average 10 years

1. Change in LVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
時間枠:Through study completion, on average 10 years

2. Change in RVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
時間枠:Through study completion, on average 10 years

3. Change in cardiac disease activity from pre-treatment to on treatment and post-treatment cessation as assessed by FDG-PET Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
時間枠:Through study completion, on average 10 years

4. Atrial fibrillation burden (from ICD and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
時間枠:Through study completion, on average 10 years

5. Ventricular arrhythmia burden, including PVC burden (from ICD diagnostics and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
時間枠:Through study completion, on average 10 years

6. Appropriate ICD therapy Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
時間枠:Through study completion, on average 10 years

7. Percentage (%) of ventricular pacing Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
時間枠:Through study completion, on average 10 years

8. AV nodal function Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Silent Disease and Control Patients
時間枠:Through study completion, on average 10 years

1. Development of Clinically Manifest CS Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Pablo Nery, MD、Ottawa Heart Institute Research Corporation
  • 主任研究者:Rob Beanlands, MD、Ottawa Heart Institute Research Corporation
  • 主任研究者:David Birnie, MD、Ottawa Heart Institute Research Corporation

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2012年8月1日

一次修了 (推定)

2027年3月1日

研究の完了 (推定)

2035年12月1日

試験登録日

最初に提出

2011年11月10日

QC基準を満たした最初の提出物

2011年11月18日

最初の投稿 (推定)

2011年11月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年10月30日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • UOHI-04

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。